The regulation of estrogenic and antiestrogenic effects of selective estrogen receptor modulators (SERMs) is thought to underlie their clinical use. Most SERMs are polyaromatic phenols susceptible to ...

In women at increased risk for BC, tamoxifen (20 mg/d for 5 years) may be offered to reduce the risk of invasive ER-positive BC, with benefits for at least 10 years. In postmenopausal women, ...

We searched for studies that used estrogen alone; estrogen in combination with progestogens; synthetic steroids, (such as tibolone); selective estrogen receptor modulators (SERMs, that affect how ...

Only 2 SERMs (tamoxifen and raloxifene) are currently available by prescription, and their approved indications are limited; however, a number of newer SERMs are in development.

Walsh and colleagues [26] conducted a 6-month trial comparing the effects of daily doses of 60 mg raloxifene, 120 mg raloxifene, 0.625 CEE plus 2.5 mg MPA, and placebo.

SERMs, such as raloxifene and bazedoxifene, can also prevent bone loss in postmenopausal women with osteoporosis (LeBoff et al., 2022). PTH analogs, including teriparatide and abaloparatide, act as ...

Despite exhibiting promising efficacy in managing postmenopausal osteoporosis, hormonal therapy, and breast cancer prevention, the usage of raloxifene hydrochloride (RLX) is limited in clinical ...